(Q30584453)

English

Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

1 reference

based on heuristic

inferred from title

Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

1 reference

based on heuristic

inferred from title

author name string

Camilla Niva

1

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Joanna Parkinson

2

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Fredrik Olsson

3

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Erno van Schaick

4

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Johan Lundkvist

5

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Sandra A G Visser

6

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

publication date

4 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

European Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

1247-1260

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

2012 Alzheimer's disease facts and figures

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

The amyloid hypothesis for Alzheimer's disease: a critical reappraisal

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

γ-Secretase inhibitors and modulators for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Alzheimer's disease and the amyloid β-protein

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Regulated intramembrane proteolysis--lessons from amyloid precursor protein processing

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Alzheimer's disease: strategies for disease modification

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

BACE-1 inhibition prevents the γ-secretase inhibitor evoked Aβ rise in human neuroblastoma SH-SY5Y cells

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

The dynamics of Aβ distribution after γ-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Modeling effect of a γ-secretase inhibitor on amyloid-β dynamics reveals significant role of an amyloid clearance mechanism

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Global issues in drug development for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Parameter estimability of biphasic response models.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1459-3

21 January 2018

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Physiologic indirect response models characterize diverse types of pharmacodynamic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interplay between α-, β-, and γ-secretases determines biphasic amyloid-β protein level in the presence of a γ-secretase inhibitor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers

1 reference

https://pubmed.ncbi.nlm.nih.gov/23288352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00228-012-1459-3

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30584453&oldid=2194947073"